Imidazenil, a non-sedating anticonvulsant benzodiazepine, is more potent than diazepam in protecting against DFP-induced seizures and neuronal damage

Toxicology

Volumn 256, Issue 3, 2009, Pages 164-174

  Kadriu, Bashkim ^a   Guidotti, Alessandro ^a   Costa, Erminio ^a   Auta, James ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

DFP; Diazepam; Imidazenil; Neuronal damage; Rats; Seizures

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ATROPINE; DIAZEPAM; DYFLOS; IMIDAZENIL; NEURON SPECIFIC NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CINGULATE GYRUS; CONTROLLED STUDY; DENTATE GYRUS; DISEASE SEVERITY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HIPPOCAMPUS; MALE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BRAIN; CHOLINESTERASE INHIBITORS; DIAZEPAM; DNA FRAGMENTATION; ELECTROENCEPHALOGRAPHY; IMIDAZOLES; IN SITU NICK-END LABELING; ISOFLUROPHATE; MALE; NEURONS; RATS; RATS, INBRED F344; SEIZURES; STATUS EPILEPTICUS; TELEMETRY;

RATTUS;

EID: 58349102708     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.11.021     Document Type: Article

References (54)

1. A receptors exhibit low tolerance liabilities in rat. J. Pharmacol. Exp. Ther. 270 (1994) 1262-1269
2. A receptors on complex behavioral processes in monkeys. Behav. Pharmacol. 6 (1995) 323-332
3. Auta J., Guidotti A., and Costa E. Imidazenil prevention of Alprazolam-induced acquisition deficits in Patas monkeys is devoid of tolerance. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2314-2319
4. Auta J., Impagnatiello F., Kadriu B., Guidotti A., and Costa E. Imidazenil: A low efficacy agonist at alpha-1 but high efficacy at alpha5-GABAA receptors fails to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology 55 (2008) 148-153
5. Auta J., Costa E., Davis J., and Guidotti A. Imidazenil: a potent and safe protective agent against diisopropyl fluorophosphate toxicity. Neuropharmacology 46 (2004) 397-403
6. Ben-Ari Y., Tremblay E., Riche D., Ghilini G., and Naquet R. Electrographic, clinical and pathological alterations following systemic administration of kainic acid, bicuculline or pentetrazole: metabolic mapping using the deoxyglucose method with special reference to the pathology of epilepsy. Neuroscience 6 (1981) 1361-1391
7. Brown M.A., and Kelley B.A. Review of health consequences from high-, intermediate- and low-level exposure to organophosphorous nerve agents. J. Appl. Toxicol. 18 (1998) 393-408
8. Carpentier P., F0quin-Tarricone A., Bodjarian N., Rondouin G., Lerner-Natoli M., Kamenka J.M., Blanchet G., Denoyer M., and Lallement G. Anticonvulsant and antilethal effects of the phencyclidine derivative TCP in soman poisoning. Neurotoxicology 15 (1994) 837-852
9. Carpentier P., Foquin A., Rondouin G., Lerner-Natoli M., DeGroot D.M.G., and Lallement G. Effects of atropine sulfate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology. Neurotoxicology 21 4 (2000) 521-540
10. A receptors. In: Mohler H. (Ed). Handbook of Experimental Pharmacology vol. 50 (2001), Springer Verlag, Berlin 227-250
11. A receptors and benzodiazepines: a role for dendritic subunit mRNAs. Neuropharmacology 43 (2002) 925-937
12. Costa E., Grayson D.R., Mitchell C.P., Tremolizzo L., Veldic M., and Guidotti A. Cortical GABAergic neuron chromatin as putative target to treat schizophrenia symptomatology. Crit. Rev. Neurobiol. 15 (2003) 121-142
13. Couteaux R., Grundfest H., Nachamansohn D., and Rothenberg M.A. Effect of diisopropyl fluorophosphate (DFP) on the action potential of muscle. Science 104 2701 (1946) 317
14. Davoli M.A., Fortunis J., Tam J., Xanthoudakis S., Nicholdon D., Ng G.S., Ng G.Y.K., and Xu S. Immunohistochemical and biochemical assessment of caspase-3 activation and DNA fragmentation following transient ischemia in the rat. Neuroscience 115 (2002) 125-136
15. Dawson R.M. Review of oximes available for the treatment of nerve agent poisoning. J. Appl. Toxicol. 14 (1994) 317-331
16. De Condole C.A., Douglas W.W., Lovett-Evans C., Holmes R., Spencer K.E.V., Torrance R.W., and Wilson K.M. The failure of respiration in death by anticholinesterase poisoning. Br. J. Pharmacol. Chemother. 8 (1953) 466-475
17. Gillis R.A., Namath I.J., Easington C., Abrahams T.P., Guidotti A., Quest J.A., Hamosh P., and Taveira da Silvia A.M. Drug interaction with GABA/benzodiazepine receptors at ventral surface of the medulla results in pronounced changes in cardio-respiratory center activity. J. Pharmacol. Exp. Ther. 248 2 (1989) 863-870
18. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493-501
19. A receptors. J. Pharmacol. Exp. Ther. 266 (1993) 1018-1028
20. Guidotti A., Auta J., Davis J.M., Dong E., Grayson D.R., Veldic M., Zhang X., and Costa E. GABAergic dysfunction in schizophrenia: a new treatment target on horizon. Psychopharmacology (Berlin) 180 (2005) 191-205
21. Gunderson C.H., Lehmann C.R., Sidell F.R., and Jabbari B. Nerve agents: a review. Neurology 42 5 (1992) 946-950
22. Fitzgerald A.L., Juneau P., Cain C., and Southwick K. Development of a quantitative method for evaluation of the electroencephologram of rats by using radio telemetry. Comtemp. Top. Lab. Anim. Sci. 42 1 (2003) 40-45
23. Hayward I.J., Wall H.G., Jaax N.K., Wade J.V., Marlow D.D., and Nold J.B. Decreased brain pathology in organophosphate exposed rhesus monkeys following benzodiazepine therapy. J. Neurol. Sci. 98 (1990) 99-106
24. Holopainen I.E. Seizures in the developing brain: cellular and molecular mechanisms of neuronal damage, neurogenesis and cellular organization. Neurochem. Int. 52 6 (2008) 935-947
25. Hopkins K.J., Wang G.J., and Schmued L.C. Temporal progression of kainic acid induced neuronal and myelin degeneration in the rat forebrain. Brain Res. 864 (2000) 69-80
26. Igarashi T., Huang T.T., and Noble L.J. Regional vulnerability after traumatic brain injury: gender differences in mice that over express human copper, zinc superoxide dismutase. Exp. Neurol. 172 (2001) 332-341
27. A receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol. 491 (1996) 822-831
28. Lallement G., Clarencon D., Galonnier M., Baubichon D., Burckhart M.F., and Peoc'h M. Acute soman poisoning in primates neither pretreated nor receiving immediate therapy: value of gacyclidine (GK-11) in delayed medical support. Arch. Toxicol. 73 2 (1999) 115-122
29. Leikin J.B., Thomas R.G., Walter F.G., Klein R., and Meislin H.W. A review of nerve agent exposure for critical care physician. Crit. Care Med. 10 (2002) 2346-2354
30. Lipp J.A. Effect of diazepam upon soman-induced seizure activity and convulsions. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 557-560
31. Martin L.J., Doebler J.A., Shih T.M., and Anthony A. Protective effect of diazepam pretreatment on soman-induced brain lesion formation. Brain Res. 325 (1985) 287-289
32. Mazur A., and Bodansky O. The mechanism of in vivo and in vitro inhibition of cholinesterase activity by diisopropyl fluorophosphate. J. Biol. Chem. 163 (1946) 261
33. McDonough J.H., Jaax N.K., Crowley R.A., Mays M.Z., and Modrow H.E. Atropine and/or diazepam therapy protects against soman-induced neuronal cardiac pathology. Fundam. Appl. Toxicol. 13 (1989) 256-276
34. McDonough J.H., and Shih T.M. Pharmacological modulation of soman-induced seizures. Neurosci. Biobehav. Rev. 21 (1993) 559-579
35. McDonough J.H., Dochterman L.W., Smith C.D., and Shih T.M. Protection against nerve agent-induced neuropathology, but not cardiac pathology, is associated with the anticonvulsant action of drug treatment. Neurotoxicology 15 (1995) 123-132
36. McDonough J.H., Clark T.R., Slone T.W., Zoeffel D., Brown K., Kim S., and Smith C.D. Neural lesions in the rat and their relationship to EEG delta activity following seizures induced by the nerve agent soman. Neurotoxicology 19 (1998) 381-392
37. Nordt S.P., and Clark R.F. Midazolam: a review of therapeutic uses and toxicity. J. Emerg. Med. 15 3 (1997) 357-365
38. Ogutu B.R., Newton C.R., Crawley J., Mucholi S.N., Otieno G.O., Edwards G., Marsh K., and Kokwaro G.O. Pharmacokinetic and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br. J. Clin. Pharmacol. 53 1 (2002) 49-57
39. Olney J.W., Rhee V., and Ho O.L. Kainic acid: a powerful neurotoxic analogue of glutamate. Brain Res. 77 (1974) 507-515
40. Phillipens I.H.C.H.M., Melchers B.P.C., DeGroot D.M.G., and Wolthius O.L. Behavioral performance, brain histology and EEG sequela after immediate combine atropine/diazepam treatment of soman-intoxicated rats. Pharmacol. Biochem. Behav. 42 (1992) 711-719
41. Rickett D.L., Glenn J.F., and Beers E.T. Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology 7 (1986) 225-236
42. Riss J., Cloyd J., Gates J., and Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol. Scand. 118 (2008) 69-86
43. Rump S., Gidynska T., Galecka E., Antkowiak O., Nawrocka M., and Kowalczyk M. Effects of imidazenil, a new benzodiazepine receptor partial agonist, in the treatment of convulsions in organophosphate intoxications. Neurotoxicol. Res. 2 (2000) 17-22
44. Sanker R., Shin D.H., Liu H., Marazati A., Pereira de Vasconcelos A., and Wasterlain C.G. Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J. Neurosci. 18 20 (1998) 8382-8393
45. Schmued L.C., Albertson C., and Slikker Jr. W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751 (1997) 37-46
46. Schwartz-Bloom R.D., McDonough K.J., Chase P.J., Chadwick L.E., Inglefield J.R., and Levin E.D. Long-term neuroprotection by benzodiazepine: full versus partial agonists after transient cerebral ischemia in the gerbil. J. Cereb. Blood Flow Metab. 18 (1998) 548-558
47. Shih T.M. Anticonvulsant effect of diazepam and MK801 in soman poisoning. Epilepsy Research 7 2 (1990) 105-116
48. Shih T.M., and McDonough H. Efficacy of biperiden and atropine as anticonvulsants treatment for organophosphate nerve agent intoxication. Arch. Toxicol. 74 3 (2000) 1165-1172
49. Shih T.M., Duniho S.M., and McDonough J.H. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 188 (2003) 69-80
50. Shih T.M., Rowland T.C., and McDonough J.H. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine. J. Pharmacol. Exp. Ther. 320 (2007) 154-161
51. Solberg Y., and Belkin M. The role of excitotoxicity in organophosphate nerve agent central poisoning. Trends Pharmacol. Sci. 18 (1997) 183-185
52. Sperk G., Lassmann H., Baran H., Kish S.J., Seitelberg F., and Hornykiewicz O. Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience 10 (1983) 1301-13015
53. Taylor P. Anticholinesterase agents. In: Hardman J.G., and Limbird L.E. (Eds). The Pharmacological Basis of Therapeutics. third ed. (1996), McGraw-Hill, New York 161-176
54. West M.J., and Slomanka L. 2-D versus 3-D cell counting-a debate. Trends Neurosci. 24 7 (2001) 374